Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004603410 | Cervix | CC | ATP metabolic process | 90/2311 | 277/18723 | 7.90e-19 | 2.36e-15 | 90 |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:00090609 | Cervix | CC | aerobic respiration | 60/2311 | 189/18723 | 1.59e-12 | 6.36e-10 | 60 |
GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:200124210 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway | 52/2311 | 164/18723 | 5.06e-11 | 1.01e-08 | 52 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:004361810 | Cervix | CC | regulation of transcription from RNA polymerase II promoter in response to stress | 21/2311 | 47/18723 | 3.85e-08 | 2.53e-06 | 21 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413718 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413719 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa0465911 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa0521114 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406619 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
HIF1A | MLUM | Breast | Healthy | TGM2,BZW1,NAMPT, etc. | 4.62e-01 | |
HIF1A | MES | Cervix | CC | HIF1A-AS3,SNAPC1,KRT6C, etc. | 7.02e-01 | |
HIF1A | PERI | Colorectum | FAP | SSH1,NUAK1,RUNX1, etc. | 4.34e-02 | |
HIF1A | ICAF | Colorectum | SER | SSH1,NUAK1,RUNX1, etc. | 3.93e-01 | |
HIF1A | PMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 2.12e-01 | |
HIF1A | GMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 1.31e-01 | |
HIF1A | PMC | Stomach | SIM | PLPP3,SERPINA3,SOD2, etc. | 4.96e-01 | |
HIF1A | GMC | Stomach | WIM | PLPP3,SERPINA3,SOD2, etc. | 7.45e-02 | |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | SP-600125 | SP-600125 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | LEVONORDEFRIN | LEVONORDEFRIN | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | DNDI1417388 | CHEMBL1528359 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NOSCAPINE | NOSCAPINE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NSC-117079 | CHEMBL471225 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | TYRPHOSTIN A9 | TYRPHOSTIN A9 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PX-478 | PX-478 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PIMOZIDE | PIMOZIDE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | BECLOMETHASONE | BECLOMETHASONE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | GELDANAMYCIN | GELDANAMYCIN | 12811834 |